Myriad has recently reported its best financial quarter ever, projecting more than $500 million in revenue from its various BRCA tests in 2013. It runs an efficient laboratory and secures third-party payment. Moreover, all 3 CAFC judges agreed that Myriad could obtain patents on claims for primers, probes, and DNA constructs it made and disclosed. However, the Supreme Court seems to be poised to judge that Myriad's claims reached too far to secure exclusive rights on naturally occurring DNA sequences. If so, companies developing molecular diagnostics will have to comport with a new rule for U.S. patent jurisprudence: Yes, cDNA can be patented, but not genomic DNA.